BRAF and neoplasm: However, validation of the BRAF V600E mutation IHC specificity by comparative molecular analysis should be performed for each tumor entity before routine diagnostic implementation, since it has been recently reported that in pituitary adenomas, the BRAF V600E mutation-specific VE1 immunostaining is not associated with presence of BRAF V600E mutation [35].